David Stenehjem, PharmD, BCOP

David Stenehjem

213 Life Science
1110 Kirby Drive
Duluth, MN 55812
United States

Professional Associations

American Society of Clinical Oncology (2015-present)

American Pharmacists Association (2005 to 2012)

American Society of Heath-System Pharmacists (2005 to 2012)

Hematology/Oncology Pharmacy Association (2010 to present)

Minnesota Pharmacy Student Alliance (2005 to 2009)

Minnesota Society of Health-System Pharmacists (2005 to 2009)

Rho Chi Academic Honors Society in Pharmacy (2006-2009)

Utah Society of Health-System Pharmacists (2009 to present)


Associate Professor and Associate Department Head, Department of Pharmacy Practice and Pharmaceutical Sciences

Hematology/Oncology Pharmacy Specialty Resident, Post Graduate Year Two: Huntsman Cancer Hospital at the University of Utah Hospitals and Clinics, 2011


Pharmacy Practice Resident, Post Graduate Year One: University of Utah Hospitals and Clinics, 2010

PharmD, University of Minnesota, College of Pharmacy-Duluth, 2009

Expand all



Published peer reviewed:

1. Stenehjem, D. D., Hahn, A. W., Gill, D. M., Albertson, D., Gowrishankar, B., Merriman, J., Agarwal, A. M., Thodima, V., Harrington, E. B., Au, T. H., Maughan, B. L., Houldsworth, J., Pal, S. K., & Agarwal, N. (2019). Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma. PLOS ONE, 14(1), e0210415. doi: 10.1371/journal.pone.0210415 doi: 10.1371/journal.pone.0210415

2. Wilairat, P., Kengkla, K., Kaewpanan, T., Kaewthong, J., Ruankon, S., Subthaweesin, C., Stenehjem, D. D., & Saokaew, S. (2018). Comparative efficacy and safety of interventions for preventing chemotherapy-induced oral mucositis in adult cancer patients: A systematic review and network meta-analysis. European Journal of Hospital Pharmacy. doi: 10.1136/ejhpharm-2018-001649 doi: 10.1136/ejhpharm-2018-001649

3. Weldon Gilcrease, G., Stenehjem, D. D., Wade, M. L., Weis, J., McGregor, K., Whisenant, J., Boucher, K. M., Thorne, K., Orgain, N., Garrido-Laguna, I., & Sharma, S. (2018). Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first–line treatment of metastatic colorectal cancer. Investigational New Drugs. doi: 10.1007/s10637-018-0645-2 doi: 10.1007/s10637-018-0645-2

4. Hahn, A. W., Froerer, C., VanAlstine, S., Rathi, N., Bailey, E. B., Stenehjem, D. D., & Agarwal, N. (2018). Targeting Bacteroides in Stool Microbiome and Response to Treatment With First-Line VEGF Tyrosine Kinase Inhibitors in Metastatic Renal-Cell Carcinoma. Clinical Genitourinary Cancer, 16(5), 365-368. doi: 10.1016/j.clgc.2018.05.001 doi: 10.1016/j.clgc.2018.05.001

Co-senior author

5. Stenehjem, D. D., Tran, D.*, Nkrumah, M. A., & Gupta, S. (2018). PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer. OncoTargets and Therapy, 11, 5973-5989. doi: 10.2147/OTT.S135157 doi: 10.2147/OTT.S135157

6. Stevens, V. W., Stenehjem, D. D., Patterson, O. V., Kamauu, A. W.C., Yim, Y. M., Morlock, R. J., & DuVall, S. L. (2018). Characterization and survival of patients with metastatic basal cell carcinoma in the Department of Veterans Affairs: a retrospective electronic health record review. Archives of Dermatological Research, 310(6), 505-513. doi: 10.1007/s00403-018-1834-8 doi: 10.1007/s00403-018-1834-8

7. Stenehjem, D. D., Cavalieri, C., Swanson, E., Solomon, B., Whisenant, J., Tran, D., Weis, J., Gilcrease, G., Sharma, S., & Garrido-Laguna, I. (2018). Pembrolizumab in advanced gastrointestinal malignancies with defective dna mismatch repair: A case series. J Immunother Precis Oncol, 1(1), 1--6. doi: 10.4103/JIPO.JIPO_5_18 doi: 10.4103/JIPO.JIPO_5_18

8. Olander, M.*, Waring, S., Stenehjem, D. D., Taran, A., Raneli, P. L., & Brown, J. (2018). Primary Care Clinicians Attitudes and Knowledge of Pharmacogenetics in a Large, Multi-state, Healthcare System. INNOVATIONS in pharmacy, 9(2), 6. doi: 10.24926/iip.v9i2.970 doi: 10.24926/iip.v9i2.970

9. Bailey, E. B., Merriman, J., Maughan, B., Poole, A., Tantravahi, S. K., Agarwal, A. M., Batten, J. A., Patel, S. B., Pal, S. K., Stenehjem, D. D., & Agarwal, N. (2018). Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors. Journal of Oncology Pharmacy Practice, 24(3), 190-197. doi: 10.1177/1078155217693426 doi: 10.1177/1078155217693426

10. Stenehjem, D. D., Au, T., Sainski, A. M., Bauer, H., Brown, K., Lancaster, J., Stevens, V., & Brixner, D. I. (2018). Impact of a genetic counseling requirement prior to genetic testing. BMC Health Services Research, 18(1). doi: 10.1186/s12913-018-2957-5 doi: 10.1186/s12913-018-2957-5

11. Wu, Y. P., Stenehjem, D. D., Linder, L. A., Yu, B., Parsons, B. G., Mooney, R., & Fluchel, M. N. (2018). Adherence to Oral Medications During Maintenance Therapy Among Children and Adolescents With Acute Lymphoblastic Leukemia: A Medication Refill Analysis. Journal of Pediatric Oncology Nursing, 35(2), 86-93. doi: 10.1177/1043454217741877 doi: 10.1177/1043454217741877

12. Gilreath, J. A., Wei, M., Paul, S., Parker, C. J., Stenehjem, D. D., & Rodgers, G. M. (2018). Dynamic dosing of romiplostim in patients with immune thrombocytopenia purpura: Two case reports. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 1078155217752536. doi: 10.1177/1078155217752536 doi: 10.1177/1078155217752536

13. Jahn, B., Rochau, U., Kurzthaler, C., Hubalek, M., Miksad, R., Sroczynski, G., Paulden, M., Bundo, M., Stenehjem, D., Brixner, D., Krahn, M., & Siebert, U. (2017). Personalized treatment of women with early breast cancer: A risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online. BMC Cancer, 17(1). doi: 10.1186/s12885-017-3603-z doi: 10.1186/s12885-017-3603-z

14. Gill, D., Gaston, D., Bailey, E., Hahn, A., Gupta, S., Batten, J., Alex, A., Boucher, K., Stenehjem, D., & Agarwal, N. (2017). Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone. Clinical Genitourinary Cancer, 15(4), e599-e602. doi: 10.1016/j.clgc.2016.12.008 doi: 10.1016/j.clgc.2016.12.008

15. Nelson, K. L., Stenehjem, D. D., Driscoll, M., & Gilcrease, G. W. (2017). Fatal Statin-Induced Rhabdomyolysis by Possible Interaction with Palbociclib. Frontiers in Oncology, 7, 3420. doi: 10.3389/fonc.2017.00150 doi: 10.3389/fonc.2017.00150

16. Au, T. H., Wang, K., Stenehjem, D. D., & Garrido-Laguna, I. (2017). Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. Journal of Gastrointestinal Oncology, 8(3), 387-404. doi: 10.21037/jgo.2017.01.04 doi: 10.21037/jgo.2017.01.04

17. Kuzman, J. A., Stenehjem, D. D., Merriman, J., Agarwal, A. M., Patel, S. B., Hahn, A. W., Alex, A., Albertson, D., Gill, D. M., & Agarwal, N. (2017). Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma. BMC Urology, 17(1), 1. doi: 10.1186/s12894-016-0192-0 doi: 10.1186/s12894-016-0192-0

Co-first author.

18. Au, T. H., Cavalieri, C. C., & Stenehjem, D. D. (2016). Ceritinib: A primer for pharmacists. Journal of Oncology Pharmacy Practice. doi: 10.1177/1078155216672315 doi: 10.1177/1078155216672315

19. Stenehjem, D. D., Udomaksorn, S., Cheng, Y., Pflieger, L., Au, T. H., Buys, S. S., & Brixner, D. I. (2016). Evaluation of the relevance and access of EHR-based variables to support personalized medicine in breast cancer. Cogent Medicine, 3(1). doi: 10.1080/2331205x.2016.1234661 doi: 10.1080/2331205x.2016.1234661

20. Gill, D. M., Stenehjem, D. D., Parikh, K., Merriman, J., Sendilnathan, A., Agarwal, A. M., Hahn, A. W., Gupta, S., Tantravahi, S. K., Samlowski, W. E., & Agarwal, N. (2016). Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2. ecancermedicalscience, 10, 676. doi: 10.3332/ecancer.2016.676 doi: 10.3332/ecancer.2016.676

21. Stenehjem, D. D., Toole, M., Merriman, J., Parikh, K., Daignault, S., Scarlett, S., Esper, P., Skinner, K., Udager, A., Tantravahi, S. K., Gill, D., Straubhar, A. M., Agarwal, A. M., Grossmann, K. F., Samlowski, W. E., Redman, B., Agarwal, N., & Alva, A. (2016). Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2. Cancer Immunology, Immunotherapy, 65(8), 941-9. doi: 10.1007/s00262-016-1854-1 doi: 10.1007/s00262-016-1854-1

22. Patel, S. B., Stenehjem, D. D., Gill, D. M., Tantravahi, S. K., Agarwal, A. M., Hsu, J., Vuong, W., Pal, S. K., & Agarwal, N. (2016). Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies. Clinical Genitourinary Cancer, 14(2), 153-9. doi: 10.1016/j.clgc.2015.12.011 doi: 10.1016/j.clgc.2015.12.011

Co-first author with Dr. Patel.

23. Unni, S. K., Schauerhamer, M. B., Deka, R., Tyczynski, J. E., Fernandes, A. W., Stevens, V., Brixner, D. I., & Stenehjem, D. D. (2016). BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study. Journal of Ovarian Research, 9, 18. doi: 10.1186/s13048-016-0227-x doi: 10.1186/s13048-016-0227-x

24. Stenehjem, D. D., Bellows, B. K., Yager, K. M., Jones, J., Kaldate, R., Siebert, U., & Brixner, D. I. (2016). Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer. The Oncologist, 21(2), 196-204. doi: 10.1634/theoncologist.2015-0162 doi: 10.1634/theoncologist.2015-0162

25. Akoum, N., Bader, F., Ghanem, M., Stenehjem, D., Burningham, Z., & Sauer, B. C. (2016). Comparison of the effectiveness and side effects of dofetilide and dronedarone in the treatment of atrial fibrillation during an indicated period in time with perceived equipoise. F1000Research, 5. doi: 10.12688/F1000RESEARCH.7908.1 doi: 10.12688/F1000RESEARCH.7908.1

26. Rochau, U., Sroczynski, G., Wolf, D., Schmidt, S., John, B., Kluibenschaedl, M., Conrads-Frank, A., Stenehjem, D. D., Brixner, D. I., Radich, J., Gastl, G., & Siebert, U. (2015). Cost-Effectiveness of the Sequential Application of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia. Leukemia and Lymphoma, 56(8), 1-11. doi: 10.3109/10428194.2014.982635 doi: 10.3109/10428194.2014.982635

27. Rochau, U., Kluibenschaedl, M., Stenehjem, D. D., Kuan-Ling, K., Radich, J., Oderda, G., Brixner, D. I., & Siebert, U. (2015). Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis. Leukemia Research and Treatment, 1-13. doi: 10.1155/2015/982395 doi: 10.1155/2015/982395

28. Kuo, K.-L., Stenehjem, D. D., Albright, F., Ray, S., & Brixner, D. I. (2015). Treatment Patterns and Outcomes in Patients with Hepatocellular Carcinoma Stratified by Stage-Guided Treatment Categories. Journal of the National Comprehensive Cancer Network, 13(8), 987-994. doi: 10.6004/jnccn.2015.0119 doi: 10.6004/jnccn.2015.0119

29. Bailey, H., Stenehjem, D. D., & Sharma, S. (2015). Panobinostat for the treatment of multiple myeloma: the evidence to date. Journal of Blood Medicine, 6, 269-276. doi: 10.2147/JBM.S69140 doi: 10.2147/JBM.S69140

30. Siebert, U., Jahn, B., Rochau, U., Schnell-Inderst, P., Kisser, A., Hunger, T., Sroczynski, G., Mühlberger, N., Willenbacher, W., Schnaiter, S., Endel, G., Huber, L., Gastl, G., & Oncotyrol HTA & Outcomes Research Working Group (2015). Oncotyrol – Center for Personalized Cancer Medicine: Methods and Applications of Health Technology Assessment and Outcomes Research. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen, 109(4-5), 330-340. doi: 10.1016/j.zefq.2015.06.012 doi: 10.1016/j.zefq.2015.06.012

31. Bailey, E. B., Tantravahi, S. K., Poole, A., Agarwal, A. M., Straubhar, A. M., Batten, J. A., Patel, S. B., Wells, C. E., Stenehjem, D. D., & Agarwal, N. (2015). Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors. Clinical Genitourinary Cancer, 13(3), e131-7. doi: 10.1016/j.clgc.2014.11.002 doi: 10.1016/j.clgc.2014.11.002

32. Tantravahi, S. K., Albertson, D., Agarwal, A. M., Ravulapati, S., Poole, A., Patel, S. B., Hawatmeh, J. S., Straubhar, A. M., Liu, T., Stenehjem, D. D., & Agarwal, N. (2015). Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma. Journal of Oncology, 2015(2), 1-6. doi: 10.1155/2015/181926 doi: 10.1155/2015/181926

33. Reese, Z., Patel, S., Stenehjem, D. D., & Garrido-Laguna, I. (2014). Response to nab-paclitaxel plus gemcitabine in a patient with primary resistance to FOLFIRINOX. Journal of Gastrointestinal Cancer, 45 Suppl 1, 278-281. doi: 10.1007/s12029-014-9662-3 doi: 10.1007/s12029-014-9662-3

34. Stenehjem, D. D., Yoo, M., Unni, S. K., Singhal, M., Bauer, H., Saverno, K., Quah, C., Masaquel, A., & Brixner, D. I. (2014). Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer. Breast Cancer: Targets and Therapy, 6, 169-177. doi: 10.2147/BCTT.S69416 doi: 10.2147/BCTT.S69416

35. Stenehjem, D. D., Albright, F., Kuo, K.-L., Raimundo, K., Bauer, H., Shami, P. J., Deininger, M. W., Chen, L., & Brixner, D. I. (2014). Response monitoring, tolerability, and effectiveness of imatinib treatment for chronic myeloid leukemia in a retrospective research database. Journal of the National Comprehensive Cancer Network, 12(8), 1113-1121. doi: 10.6004/jnccn.2014.0108 doi: 10.6004/jnccn.2014.0108

36. Gilreath, J. A., Stenehjem, D. D., & Rodgers, G. M. (2014). Diagnosis and treatment of cancer-related anemia. American Journal of Hematology, 89(2), 203-212. doi: 10.1002/ajh.23628 doi: 10.1002/ajh.23628

37. Nelson, R. E., Stenehjem, D. D., & Akerley, W. (2013). A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis. Lung Cancer, 82(3), 461-468. doi: 10.1016/j.lungcan.2013.08.021 doi: 10.1016/j.lungcan.2013.08.021

38. Kuo, K.-L. L., Saokaew, S., & Stenehjem, D. D. (2013). The pharmacoeconomics of breakthrough cancer pain. Journal of Pain & Palliative Care Pharmacotherapy, 27(2), 167-75. doi: 10.3109/15360288.2013.787137 doi: 10.3109/15360288.2013.787137

39. Saverno, K. R., Rochau, U., Stenehjem, D. D., Morley, K., Siebert, U., & Brixner, D. I. (2012). Application of decision-analytic models in personalized medicine for CML treatment decisions made by payers, providers, and patients. Journal of Managed Care Pharmacy, 18(6), 457-63. doi: 10.18553/jmcp.2012.18.6.457 doi: 10.18553/jmcp.2012.18.6.457

40. Gilreath, J. A., Stenehjem, D. D., & Rodgers, G. M. (2012). Total dose iron dextran infusion in cancer patients: Is it SaFe2+? Journal of the National Comprehensive Cancer Network, 10(5), 669-676. doi: doi: 10.6004/jnccn.2012.0066 doi: doi: 10.6004/jnccn.2012.0066

41. Cirulli, J., McMillian, W. D., Saba, M., & Stenehjem, D. D. (2011). Adaptive trial design: Its growing role in clinical research and implications for pharmacists. American Journal of Health-System Pharmacy, 68(9), 807-813. doi: 10.2146/ajhp100298 doi: 10.2146/ajhp100298

42. Stenehjem, D. D., Hartz, A. M., Bauer, B., & Anderson, G. W. (2009). Novel and emerging strategies in drug delivery for overcoming the blood-brain barrier. Future Medicinal Chemistry, 1(9), 1623-41. doi: 10.4155/fmc.09.137 doi: 10.4155/fmc.09.137

43. Westholm, D. E., Stenehjem, D. D., Rumbley, J. N., Drewes, L. R., & Anderson, G. W. (2009). Competitive inhibition of organic anion transporting polypeptide 1c1-mediated thyroxine transport by the fenamate class of nonsteroidal antiinflammatory drugs. Endocrinology, 150(2), 1025-1032. doi: 10.1210/en.2008-0188 doi: 10.1210/en.2008-0188

Published editorial contributions:

1. Brixner DI, Stenehjem DD, Ulrich C. Aspirin and Cancer Risk. JAMA Oncol. 2016 Aug 11.



PHAR 6742: Lecture, Evidence based problem analysis 1 and 2,

SAPH 8840 - 001: Lecture, Social Measurement,
Course Director

SAPH 8200: Seminar, Research Problems: Biology of Cancer Seminar, Director
Course Director

PHAR 6748 - 001: Lecture, Biopharmaceutics, Lecturer

PHAR 6748 - 001: Lecture, Biopharmaceutics, Director
Course Director

PHAR 6784: Lecture, Integrated Oncology, Lecturer

PHAR 6224: Lecture, Pharmacogenomics: Genetic Basis for Variability in Drug Response, Lecturer

SAPH 8200: Seminar, Research Problems: Precision Oncology Seminar, Discussion Guide, 2 participants
Discussion Guide

SAPH 8200: Seminar, Research Problems: Precision Oncology Seminar, Director,
Course Director


Board Certifications

Board Certified Oncology Specialist, Board of Pharmacy Specialties